CA-GLOBALITY
20.12.2022 14:01:34 CET | Business Wire | Press release
Globality, the leader in using artificial intelligence and natural language processing (NLP) to transform the procurement function, today announced it has been named by The AI Journal as the winner of the Best Use of NLP in the 2022 Global Excellence Awards.
This was the biggest year yet for the awards program with more than 250 entries being submitted from across the world. Each entry was reviewed by a 28-person judging panel from across the world with the winner being selected by achieving the highest score. This year the judging panel included representatives from industry dominating brands such as HSBC, Google, Deloitte, Microsoft, and Amazon.
Powered by cutting-edge AI technology, Globality reinvents the procurement process by automating the demand creation, supplier identification, proposal evaluation, and statement of work (SOW) creation process – completely replacing the traditional, outdated Request for Proposal. Its self-service, consumer-like interface uses NLP and machine learning to understand buyers' needs and match companies with suppliers that best meet specific project requirements, all while achieving substantial cost savings and reducing operating expenses.
“We are proud to be recognized by The AI Journal and receive the prestigious Global Excellence Award for Best Use of NLP,” said Lior Delgo, Globality Co-Founder and President. “It reflects the growth and success of Globality’s game-changing AI-powered technology that is helping industry-leading companies such as BT and Santander transform their buying models to manage their company’s spend more efficiently than ever before.
“In today's economic climate especially, sourcing more intelligently and effectively is not just critical to protecting the bottom line, it is key to driving better business outcomes which is exactly what Globality’s technology is empowering our customers to do.”
“Globality has set a high standard for innovation and creativity with its winning entry in the category Best Use of NLP. With this being the biggest year yet, it made the competition for being a finalist tough with innovative, smart, thought-provoking, results-driven entries coming in from companies of all sizes. It is fantastic to see the effort and passion be rewarded by getting the global recognition by winning at the 2022 Global Excellence Awards,” said Tom Allen, Founder and CEO of The AI Journal.
About Globality – Option 1
Globality is the leader in using leading-edge, artificial intelligence-powered technology to dramatically increase cost savings and improve business outcomes that procurement facilitates. Globality’s state-of-the-art digital solution replaces the traditional, outdated Request for Proposal, efficiently and effectively scoping needs, and matches companies with the suppliers that best meet the specific project requirements. By using Globality’s platform, companies achieve substantial cost savings and reduced operating expenses, while also delighting business stakeholders, fostering collaboration, and improving outcomes. For more information, visit www.globality.com
About The AI Journal Global Excellence Awards
The AI Journal’s Global Excellence Awards is a program that recognizes best practices, use cases, campaigns, and exceptional talent from high-performing teams and individuals from companies of all sizes around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005034/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom